Summary
Understanding the pathophysiology of SARS-CoV-2 infection is critical for therapeutics and public health intervention strategies. Viral-host interactions can guide discovery of regulators of disease outcomes, and protein structure function analysis points to several immune pathways, including complement and coagulation, as targets of the coronavirus proteome. To determine if conditions associated with dysregulation of the complement or coagulation systems impact adverse clinical outcomes, we performed a retrospective observational study of 11,116 patients who presented with suspected SARS-CoV-2 infection. We found that history of macular degeneration (a proxy for complement activation disorders) and history of coagulation disorders (thrombocytopenia, thrombosis, and hemorrhage) are risk factors for morbidity and mortality in SARS-CoV-2 infected patients - effects that could not be explained by age, sex, or history of smoking. Further, transcriptional profiling of nasopharyngeal (NP) swabs from 650 control and SARS-CoV-2 infected patients demonstrated that in addition to innate Type-I interferon and IL-6 dependent inflammatory immune responses, infection results in robust engagement and activation of the complement and coagulation pathways. Finally, we conducted a candidate driven genetic association study of severe SARS-CoV-2 disease. Among the findings, our scan identified putative complement and coagulation associated loci including missense, eQTL and sQTL variants of critical regulators of the complement and coagulation cascades. In addition to providing evidence that complement function modulates SARS-CoV-2 infection outcome, the data point to putative transcriptional genetic markers of susceptibility. The results highlight the value of using a multi-modal analytical approach, combining molecular information from virus protein structure-function analysis with clinical informatics, transcriptomics, and genomics to reveal determinants and predictors of immunity, susceptibility, and clinical outcome associated with infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by NIH grants 5R01GM109018 and 5U54CA209997 to SS, R35GM131905 to NPT, F30HL140946 to PT, and equipment grants S10OD012351 and S10OD021764 to the Columbia University Department of Systems Biology. CEM would like to thank the Scientific Computing Unit (SCU), XSEDE Supercomputing Resources, the Starr Cancer Consortium (I13-0052), and funding from the WorldQuant Foundation, The Pershing Square Sohn Cancer Research Alliance, NASA (NNX14AH50G, NNX17AB26G), the National Institutes of Health (R21AI129851, R01MH117406, R01AI151059).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by the Columbia University Irving Medical Center Institutional Review Board (IRB# AAAL0601) and the requirement for an informed consent was waived. A data request associated with this protocol was submitted to the Tri-Institutional Request Assessment Committee (TRAC) of New-York Presbyterian, Columbia, and Cornell and approved. The research on the UK Biobank data has been conducted using the UK Biobank Resource under Application Number 41039. The transcriptomics analysis samples were collected and processed through the Weill Cornell Medicine Institutional Review Board (IRB) Protocol 19-11021069.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our data from NYP/CUIMC are protected by HIPAA and cannot be released. UK Biobank data are available through their application process. In addition, we are updating online summary data as additional patient data become available.
